Steven Binder has joined the MannKind Corporation as its Chief Financial Officer with full responsibilities for leading the Valencia-based company’s finance, accounting and investor relations on a global basis, according to a MannKind news release.
Binder reports directly to Michael Castagna, Pharm.D., Chief Executive Officer and has joined the company’s executive leadership team.
Binder joins MannKind with more than 25 years of experience in the healthcare industry. He most recently spent four years at Stryker Corporation, a leading global medical technology company, where he served as Vice President and Chief Financial Officer for Stryker’s International Group, based in Singapore.
Prior to Stryker, Binder served in a series of senior leadership roles at Bristol-Myers Squibb Company, an innovative global biopharmaceutical company. His last four positions at BMS were Vice President, Finance roles over different geographic operating units: United States (2012-2013), Europe (2008-2011), AsiaPacific (2005-2007), and Japan (2003-2005).
Prior to his international experience, Binder served in three senior leadership roles for Oncology Therapeutics Network, a U.S. based independent subsidiary of BMS: Vice President, Strategic Development (2001-2003), Vice President, Customer Operations (2000-2001), and Chief Financial Officer (1997-2000).
Before OTN, Binder progressed through three finance and accounting roles for BMS Worldwide Medicines Group after joining the company in 1992.
Before BMS, he worked for Deloitte & Touche in a series of auditing roles with increasing responsibility over an eight year period beginning in 1984. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant.
“We are very excited to have Steve join MannKind and our executive leadership team. His deep experience in finance and his commercial acumen acquired through a variety of senior leadership roles in multi-national healthcare companies will be a clear competitive advantage for us,” said Dr. Castagna.
“Steve joins MannKind at an exciting period as we develop into a world-class biopharmaceutical company,” he said. “I would like to thank Rose Alinaya for her leadership as Acting Chief Financial Officer prior to Steve’s hiring. Rose will now transition to leading investor relations for MannKind, a very important capability for us moving forward, reporting directly to Steve.”
“MannKind is well-positioned for future growth and I could not be more excited about being a part of this team,” Binder said. “I believe Afrezza is an innovative product with great potential to improve the quality of life for diabetic patients.”
MannKind Corporation focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. Visit the company’s website for more information.